LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (Nasdaq: ALXN) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at email@example.com.
On November 9, 2016, Alexion announced that is investigating accusations of improper sales practices of its top drug, Soliris, which is estimated to account for 92% of the Company’s sales for 2016. The Company retained outside counsel and announced its decision to delay its third-quarter financial report.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.